Targeted therapies in breast cancer:New challenges to fight against resistance

被引:8
作者
Viviana Masoud [1 ]
Gilles Pagès [1 ]
机构
[1] University Nice Sophia Antipolis,Institute for Research on Cancer and Aging of Nice CNRS UMR7284/INSERM U 1081
关键词
Breast cancers; Resistance; Human epidermal growth factor receptor 2; Angiogenesis; Triple negative; Immune tolerance;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 ;
摘要
Breast cancer is the most common type of cancer found in women and today represents a significant challenge to public health. With the latest breakthroughs in molecular biology and immunotherapy, very specific targeted therapies have been tailored to the specific pathophysiology of different types of breast cancers. These recent developments have contributed to a more efficient and specific treatment protocol in breast cancer patients. However, the main challenge to be further investigated still remains the emergence of therapeutic resistance mechanisms, which develop soon after the onset of therapy and need urgent attention and further elucidation. What are the recent emerging molecular resistance mechanisms in breast cancer targeted therapy and what are the best strategies to apply in order to circumvent this important obstacle? The main scope of this review is to provide a thorough update of recent developments in the field and discuss future prospects for preventing resistance mechanisms in the quest to increase overall survival of patients suffering from the disease.
引用
收藏
页码:120 / 134
页数:15
相关论文
共 43 条
[1]  
PI3K/Akt/mTOR inhibitors in breast cancer[J]. Joycelyn JX Lee,Kiley Loh,Yoon-Sim Yap.Cancer Biology & Medicine. 2015(04)
[2]  
Regulation of the m RNA half-life in breast cancer[J]. Paola Griseri,Gilles Pagès.World Journal of Clinical Oncology. 2014(03)
[3]   Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer [J].
Chamberlin, Mary D. ;
Bernhardt, Erica B. ;
Miller, Todd W. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2016, 117 (11) :2454-2463
[4]  
Analysis of PI3K/mTOR pathway biomarkers and their prognostic value in women with hormone receptor positive HER2 negative early breast cancer[J] . Hamdy A. Azim,Loay Kassem,Isabelle Treilleux,Qing Wang,Mona Abu El Enein,Shady E. Anis,Thomas Bachelot.Translational Oncology . 2016
[5]  
Better Together: Targeted Combination Therapies in Breast Cancer[J] . Elisa Zanardi,Giacomo Bregni,Filippo de Braud,Serena Di Cosimo.Seminars in Oncology . 2015 (6)
[6]   Overcoming Resistance to Targeted Therapies in Cancer [J].
Redmond, Keara L. ;
Papafili, Anastasia ;
Lawler, Mark ;
Van Schaeybroeck, Sandra .
SEMINARS IN ONCOLOGY, 2015, 42 (06) :896-908
[7]   Mechanisms of lapatinib resistance in HER2-driven breast cancer [J].
D'Amato, Valentina ;
Raimondo, Lucia ;
Formisano, Luigi ;
Giuliano, Mario ;
De Placido, Sabino ;
Rosa, Roberta ;
Bianco, Roberto .
CANCER TREATMENT REVIEWS, 2015, 41 (10) :877-883
[8]  
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease[J] . Murugan Kalimutho,Kate Parsons,Deepak Mittal,J. Alejandro López,Sriganesh Srihari,Kum Kum Khanna.Trends in Pharmacological Sciences . 2015 (12)
[9]   Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway [J].
Wilks, Sharon T. .
BREAST, 2015, 24 (05) :548-555
[10]  
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways[J] . Johnston Stephen R. D..JNCI Journal of the National Cancer Institute . 2015 (10)